Cerebral Glucose Utilization in Motor Neuron Disease

Hoffman, John M.; Mazziotta, John C.; Hawk, Thomas C.; Sumida, Ron M.

doi:10.1001/archneur.1992.00530320077014

Cited by 31 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of ALS patients included in SPECT studies varies between n = 14 (Waldemar et al., 1992 ) and n = 26 (Abe et al., 1997 ), and those in PET studies varies between n = 7 (Hoffman et al., 1992 ) and n = 32 (Cistaro et al., 2012 ). Single-centre morphometric studies of ALS also show considerable variation in sample size; from n = 12 (Minnerop et al., 2009 ) to n = 45 (Verstraete et al., 2012 ).…”

Section: Resultsmentioning

confidence: 99%

Lessons of ALS imaging: Pitfalls and future directions — A critical review

Bede

Hardiman

2014

NeuroImage: Clinical

View full text Add to dashboard Cite

BackgroundWhile neuroimaging in ALS has gained unprecedented momentum in recent years, little progress has been made in the development of viable diagnostic, prognostic and monitoring markers.ObjectivesTo identify and discuss the common pitfalls in ALS imaging studies and to reflect on optimal study designs based on pioneering studies.MethodsA “PubMed”-based literature search on ALS was performed based on neuroimaging-related keywords. Study limitations were systematically reviewed and classified so that stereotypical trends could be identified.ResultsCommon shortcomings, such as relatively small sample sizes, statistically underpowered study designs, lack of disease controls, poorly characterised patient cohorts and a large number of conflicting studies, remain a significant challenge to the field. Imaging data of ALS continue to be interpreted at a group-level, as opposed to meaningful individual-patient inferences.ConclusionsA systematic, critical review of ALS imaging has identified stereotypical shortcomings, the lessons of which should be considered in the design of future prospective MRI studies. At a time when large multicentre studies are underway a candid discussion of these factors is particularly timely.

show abstract

Section: Resultsmentioning

confidence: 99%

Lessons of ALS imaging: Pitfalls and future directions — A critical review

Bede

Hardiman

2014

NeuroImage: Clinical

View full text Add to dashboard Cite

show abstract

“…Some correlation with neuropsychological impairments Ludolph et al ( 1992 ) 3 PLS Reduced uptake in pericentral cortex in 2/3 patients Pringle et al ( 1992 ) 7 ALS (3 FU); 1 PMA; 11 HC No overall group difference. Progressive decrease in glucose metabolism in precentral gyrus but increase in middle frontal gyrus with progression Hoffman et al ( 1992 ) 3 PLS with Parkinsonian signs; control database Precentral, prefrontal and cingulate uptake reductions Kono et al ( 2012 ) particularly verbal fl uency (Ludolph et al 1992 ), in keeping with the predilection of ALS to cause a dysexecutive syndrome (Phukan et al 2012 O 2 were used to measure similar reductions in regional cerebral blood fl ow (rCBF) in ALS patients with dementia (Tanaka et al 1993 ) and were also linked to abnormalities of verbal fl uency in ALS patients without overt dementia (Kew et al 1993a ).…”

Section: Blood Flow and Metabolismmentioning

confidence: 97%

Amyotrophic Lateral Sclerosis

Turner¹

2014

PET and SPECT in Neurology

View full text Add to dashboard Cite

The core of the clinical syndrome of amyotrophic lateral sclerosis (ALS) is a progressive and typically rapid degeneration of a previously normally functioning motor system, comprising upper motor neurons (UMNs) of the primary motor cortex and corticospinal tract (CST), brainstem nuclei and the lower motor neurons (LMNs) arising from the anterior horns of the spinal cord. Weakness, with variable wasting, of the musculature of the limbs and of speech and swallowing ensues, with involvement of the diaphragm resulting in respiratory insuffi ciency and a median survival of 3 years. The marked clinical heterogeneity, frequent diagnostic delay and reliance of therapeutic trials on survival as the primary outcome measure make the discovery of biomarkers in ALS a research priority.Whilst the spinal anterior horns and corticospinal tract superfi cially appear to bear the brunt of histopathology in ALS, it has been clear for over half a century that degeneration extends to involve the extra-motor brain, preferentially involving areas of the frontal and temporal lobes having clinical and genetic overlap with some forms of frontotemporal dementia (FTD).

show abstract

“…Alterations in blood flow detected by SPECT can extend into the frontal lobes, particularly in patients with abnormal cognition [170]. PET images utilizing a 2-fluoro-2-deoxy-glucose tracer demonstrate variable reductions in cerebral glucose metabolism in resting ALS patients compared to controls [171][172]. In a large crosssectional study, the sensitivity of this approach was 95.4% and the specificity was 82.5% [173].…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Further development of biomarkers in amyotrophic lateral sclerosis

Blasco

Vourc’h

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

In this review, we specifically focus on biology and imaging markers. We detail the innovative field of 'omics' approach and imaging and explain their limits to be useful in routine practice. We describe the most relevant biomarkers and suggest some perspectives for biomarker research. Expert commentary: The successive failures of clinical trials in ALS underline the need for new strategy based on innovative tools to stratify patients and to evaluate their responses to treatment. Biomarker data may be useful to improve the designs of clinical trials. Biomarkers are also needed to better investigate disease pathophysiology, to identify new therapeutic targets, and to improve the performance of clinical assessments for diagnosis and prognosis in the clinical setting. A consensus on the best management of neuroimaging and 'omics' methods is necessary and a systematic independent validation of findings may add robustness to future studies.

show abstract

Cerebral Glucose Utilization in Motor Neuron Disease

Cited by 31 publications

References 36 publications

Lessons of ALS imaging: Pitfalls and future directions — A critical review

Lessons of ALS imaging: Pitfalls and future directions — A critical review

Amyotrophic Lateral Sclerosis

Further development of biomarkers in amyotrophic lateral sclerosis

Contact Info

Product

Resources

About